

Tocilizumab (TCZ): Actemra Desensitization Process in Heart transplantation

Step 1	<p>In order to proceed to this therapy, the patient must have a</p> <p>A. documented failure with prior desensitization therapies and</p> <p>B. a panel reactive antibody (PRA) > 90 %</p>
Step 2	<p>Check Quantiferon TB gold. This test must be documented as negative within the last 12 months from the anticipated initiation of therapy.</p>
Step 3	<p>Call 3 –DRUG or email Group DUP for patient use clearance. Please compile the following information first</p> <p>Indication: Actemra Desensitization</p> <p>Name: MRN: Rm number DOB: Prior desensitization therapies: Anticipated date of initial date of IVIG-Actemra therapy: Name of Attending Physician:</p>
Step 4	<p>All patients who met criteria for Actemra Desensitization will receive</p> <ol style="list-style-type: none"> 1. IVIG 10% (2.0 g/kg [maximum 140 g per dose] on days 1 and 30) and 2. and TCZ (8 mg/kg administered on day 15, then monthly for 6 months total therapy. <p>Ordering physician - Exclusion to Infusion:</p> <ul style="list-style-type: none"> - ANC < 1000/mm³, - Platelet <100,000/mm³ - ALT or AST less than 3x ULN within 4-8 weeks after start of therapy and within the last 3 months prior to each tocilizumab maintenance infusion.

Sample Dosing Regimen	<p>The diagram shows a horizontal timeline with arrows pointing to specific time points. At 0 and 30, there are downward arrows labeled 'IVIG 2gm/kg'. At 15, 45, 75, 105, 119, 135, and 149, there are downward arrows labeled 'Tocilizumab (8mg/kg)'. Additionally, there are upward arrows at 45, 75, 105, 119, 135, and 149, which are not labeled.</p>														
Pre- Medications	<p>A. Acetaminophen 650 mg PO 30 minutes prior to infusion B. Diphenhydramine 50 mg PO 30 minutes prior to infusion C. Methylprednisolone 40 mg IVP 30 minutes prior to infusion</p>														
Infusion labs	<p>Please draw 2 red tops for HLA prior to initiation of infusion.</p>														
After premedication	<p>Tocilizumab 8 mg/kg actual body weight (_____ kg) = _____ mg in 100 ml NS Infuse over 1 hour.</p>														
Tentative Schedule for Actemra Infusions	<table border="1"> <tr> <td>Latest negative PPD/TB GOLD</td> <td>Date: _____</td> </tr> <tr> <td>Dose #1</td> <td>FEB 2017</td> </tr> <tr> <td>Dose #2</td> <td>MAR 2017</td> </tr> <tr> <td>Dose #3</td> <td>APR 2017</td> </tr> <tr> <td>Dose #4</td> <td>MAY 2017</td> </tr> <tr> <td>Dose #5</td> <td>JUNE 2017</td> </tr> <tr> <td>Dose #6</td> <td>JULY 2017</td> </tr> </table>	Latest negative PPD/TB GOLD	Date: _____	Dose #1	FEB 2017	Dose #2	MAR 2017	Dose #3	APR 2017	Dose #4	MAY 2017	Dose #5	JUNE 2017	Dose #6	JULY 2017
Latest negative PPD/TB GOLD	Date: _____														
Dose #1	FEB 2017														
Dose #2	MAR 2017														
Dose #3	APR 2017														
Dose #4	MAY 2017														
Dose #5	JUNE 2017														
Dose #6	JULY 2017														

References:

1. ACTEMRA PACKAGE INSERT:
https://www.gene.com/download/pdf/actemra_prescribing.pdf.
2. Genentech at 1-888-835-2555.

3. Vo AA, Choi J, Kim I, Louie S, Cisneros K, Kahwaji J, Toyoda M, Ge S, Haas M, Puliyananda D, Reinsmoen N, Peng A, Villicana R, Jordan SC. A Phase I/II Trial of the Interleukin-6 Receptor-Specific Humanized Monoclonal (Tocilizumab) + Intravenous Immunoglobulin in Difficult to Desensitize Patients. *Transplantation*. 2015 Nov;99(11):2356-63.
4. Choi J, Vo A, Haas M, Puliyananda D, Louie S, Peng A, Kahwaji J, Villicana R, Kim I, Mirocha J, Jordan S. Anti-IL6R Therapy (Tocilizumab) Improves Long-Term Patient & Graft Survival in Patients with Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy. *Am J Transplant*. 2016;16 (suppl 3).
5. Fernandez H, Patel S, Chiles M, Ratner L, Crew R. Tocilizumab as Treatment for Persistent Chronic Active Antibody Mediated Rejection. *Am J Transplant*. 2016;16 (suppl 3).
6. Choi J, Vo A, Kahwaji J, Haas M, Reinsmoen N, Puliyananda D, Peng A, Villicana R, Jordan S. Long Term Outcomes of Tocilizumab Therapy for DSA+ Antibody Mediated Rejection (ABMR) Resistant to IVIG + Rituxan (I+R) Treatment [abstract]. *Am J Transplant*. 2015; 15 (suppl 3).
<http://www.atcmeetingabstracts.com/abstract/long-term-outcomes-of-tocilizumab-therapy-for-dsa-antibody-mediated-rejection-abmr-resistant-to-ivig-rituxan-ir-treatment/>.
7. Kobashigawa J, Mehra M, West L, et al. Report from a consensus conference on the sensitized patient awaiting heart transplantation. *J Heart Lung Transplant* 2009;28:213-25.
8. Kobashigawa J, Crespo-Leiro MG, Ensminger SM, et al. Report from a consensus conference on antibody-mediated rejection in heart transplantation. *J Heart Lung Transplant* 2011;30:252-69
9. Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. *TN Engl J Med* 2013;369:1215-26.
10. Zeevi A, Lunz J, Feingold B, et al. Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients. *J Heart Lung Transplant* 2013;32:98-105.

11. Sutherland SM, Chen G, Sequeira FA, Lou CD, Alexander SR, Tyan DB. Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss. *Ped Transplant* 2012;16:12-7.
12. Stehlik J, Islam N, Hurst D, et al. Utility of virtual crossmatch in sensitized patients awaiting heart transplantation. *J Heart Lung Transplant* 2009;28:1129-34.
13. Cecka JM. Calculated PRA (CPRA): the new measure of sensitization for transplant candidates. *Am J Transplant* 2010;10:26-9.
14. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. *N Engl J Med* 2008;359:242-51.
15. Patel J, Everly M, Chang D, Kittleson M, Reed E, Kobashigawa J. Reduction of alloantibodies via proteasome inhibition in cardiac transplantation. *J Heart Lung Transplant* 2011;30:1320-6 - See more at: <http://www.acc.org/latest-in-cardiology/articles/2014/12/22/17/07/management-of-the-highly-sensitized-patient-awaiting-heart-transplant-expert-analysis#sthash.sPOh9b.dpuf>